Company intelligence / Profile preview
Ligand Pharmaceuticals
- Ownership
- Public · LGND
- Employees
- ~68
- Development stage
- Other
Overview
Ligand has built one of the industry’s largest portfolios of partnered royalty assets with consistent revenue streams from multiple approved drugs such as Kyprolis®, Promacta®, Melphalan®, Baxdela®, among others. Its proprietary Captisol® technology enables improved drug formulations and has been widely licensed to major pharmaceutical companies. The company continues to invest in new technologies and expand its portfolio through acquisitions and partnerships[2][3].
- Therapeutic areas
- GastroenterologyNephrologyEndocrinologyOncologyRare Diseases
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)drug delivery technologies (notably Captisol®)
- Industry
- Biotech
Drug pipeline
41 assets40 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $6B
- Total revenue
- $268.1M
- Enterprise value
- $6.7B
Beyond the preview
Go deeper on Ligand Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ligand Pharmaceuticals.